X-Zell
Early, pain-free cancer detection.
X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc
Active Founders
Sebastian Punyaratabandhu Bhakdi
Sebastian started out as a physician at the University Hospital of Freiburg, Germany and earned a Degree in International Health at the Autonomous University of Barcelona, Spain, which made him realize that health services have to be accessible for all. A Research Fellowship from the German Research Foundation helped him to create his first patent which he used to found X-ZELL. He remains its CEO and Principal Investigator, growing the company to solve the world's cancer screening challenge.
Prapat Suriyaphol
